RT Journal Article
SR Electronic
T1 <em>SF3B4</em> Plays an Oncogenic Role in Esophageal Squamous Cell Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2941
OP 2946
DO 10.21873/anticanres.14272
VO 40
IS 5
A1 SHINYA KIDOGAMI
A1 TOMOHIRO IGUCHI
A1 KUNIAKI SATO
A1 YUKIHIRO YOSHIKAWA
A1 QUINGJANG HU
A1 SHO NAMBARA
A1 HISATERU KOMATSU
A1 MASAMI UEDA
A1 YOSUKE KURODA
A1 TAKAAKI MASUDA
A1 MASAKI MORI
A1 YUICHIRO DOKI
A1 KOSHI MIMORI
YR 2020
UL http://ar.iiarjournals.org/content/40/5/2941.abstract
AB Background/Aim: The spliceosome pathway, including Splicing Factor 3b Subunit 4 (SF3B4), plays an important role in carcinogenesis and progression in various cancers; however, the clinical relevance of SF3B4 in esophageal squamous cell carcinoma (ESCC) remains unknown. Patients and Methods: SF3B4 expression was evaluated by real-time reverse transcription polymerase chain reaction in 80 ESCC patients. In order to explore the mechanism of SF3B4 in ESCC, the mRNA expression and copy number of SF3B4 were obtained from TCGA and we also implemented gene set enrichment analysis (GSEA). Results: The high SF3B4 expression group (n=33) showed significantly more lymphatic permeation and poorer prognosis than the low SF3B4 expression group (n=47). GSEA revealed that high SF3B4 expression was correlated with genes associated with the transcription factor E2F and the G2/M checkpoint. SF3B4 expression was positively correlated with SF3B4 DNA copy number. Conclusion: Over-expression of SF3B4 may play a crucial role in the lymphatic progression of ESCC.